UNSPSC 51422110: Chloroprednisone acetate

This classification denotes a therapeutic glucocorticoid C23H27ClO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z243A6BHCS, chemically known as 6.alpha.-chloro-17,21-dihydroxypregna-1,4-diene-3,11,20-trione 21-acetate, but more generally known as chloroprednisone acetate, which bears US NIH Compound Identifier 235970. European Medicines Agency schedules Chloroprednisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01231MIG.

UNSPSC 51422110 Chloroprednisone acetate is a Commodity code nominally identifying a specific corticosteroid pharmaceutical, but recent state and local opportunities tagged under this code involve broader pharmaceutical procurement—naloxone (opioid antagonist) and drug deactivation systems for community health initiatives, as well as direct-to-manufacturer prescription fulfillment programs. The mismatch between the code's nominal scope and the actual work being solicited suggests the code may be used as a catch-all for pharmaceutical supply and pharmacy benefit program transactions. State and local governments are buying naloxone and related harm-reduction supplies through the code, and state health agencies are exploring direct manufacturer relationships to manage pharmacy costs outside traditional pharmacy benefit manager and group purchasing organization channels. Issuing bodies include county health departments and state health and human services agencies; Seminole County, Florida and the Texas Health and Human Services Commission both posted opportunities under this code in the past three months.

Recent activity concentrates in Florida and Texas. Seminole County released IFB60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and workers' compensation and commercial general liability insurance. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program that would allow self-insured state employee plans and health plans to contract with pharmaceutical manufacturers outside traditional PBM and GPO arrangements. The RFI focuses on vendors' experience with negotiated net pricing models and value-based contracting; no formal award amounts, evaluation criteria, or timelines are specified in the exploratory phase.